乐竞在线官网-中国有限公司官网

Home / Education / Faculty Team / School of Pharmaceutical Sciences / Tenure Track / Content

Yuyang JIANG, Ph.D.

Prof. Dr. Jiang got his B. Sc from Shenyang Pharmaceutical University in 1986, after which he worked as an assistant Professor in Shenyang Pharmaceutical University. He got his M. Sc. and Ph. D in 1993 and 1996, respectively, from Institute of Applied Ecology, Chinese Academy of Sciences. His postdoctoral training was conducted at Tsinghua University from 1996 to 1998, after which he worked as an associate professor in the Department of Chemistry, Tsinghua University. He is currently a professor in the Department of Chemistry and School of Medicine in Tsinghua University, the director of the Guangdong Provincial Key Laboratory of Chemical Biology and the Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, the Graduate School at Shenzhen, Tsinghua University.

Personal Profile
Research interests
Selected Achievements
Other Information

Dr. Yuyang Jiang has long been engaged in tumor chemical biology research focusing on a gene 'pokemon' and two kinds of diseases 'liver cancer and breast cancer', and has obtained a series of innovative achievements in pokemon-mediated regulatory network and multi-targeted antitumor compounds development. Yuyang Jiang is an author of ~220 peer reviewed papers, 23 patent applications. He has been invited to give presentations in many national and international conferences, and has severed as reviewers for many peer-reviewed chemical biology journals. Prof. Jiang is an editorial board member of 'Protein and Peptide Letters'，'Chinese Chemical Chemistry' and 'Chinese Journal of New Drugs'.

(1) Tumor detection and diagnosis

Selective RNA-cleaving Fluorescent DNAaymes (RFD) can detect their specific ligands rapidly, sensitively, and accurately. These RFD probes have the potential to accomplish the requirement that to recognize tumors. Thus it is essential to develop tumor-specific RFD probes and the RFD detection kits. Our research is based on the SELEX technique(systematic evolution of ligands by exponential Enrichment),to obtain the DNA pool that can specifically identify tumor metabolite. RFD probe of the DNA pool can also distinguish tumor cells from normal cells and classify sub-type of tumor. It will be a new method to find biomarker for individualized treatment, tumor prevention and early diagnosis.

(2) Pokemon signaling pathways

Pokemon is a ubiquitous transcription factor of the POZ family composed of BTB/POZ domain at the N terminus and a Kruppel zinc finger domain at the C terminus. Pokemon plays a pivotal role in tumorigenesis as a proto-oncogene localized upstream of several oncogenes. It is may be efficent target for antitumor drug research. In our group, pokemon mediated tumor signal transduction pathways were studied using advanced technology and methods in the field of functional genomics and bioinformatics. Pokemon related gene regulatory networks were established in breast and liver cancers, which included cell growth, migration, apoptosis, cell cycle, multidrug resistance signaling pathways and nucleoside, amino acid, lipid material metabolism pathways. It will establishe a theoretical basis for the study on multigene regulatory network of tumor formation, selection and combination of anti-cancer drug targets with independent intellectual property rights.

(3) High-throughput screening method and multi-targeted anticancer drug discovery

Cancer is a disease of multiple genes and found novel multi-targeted drugs with high efficiency and low toxicity is important. A wide range of screening can significantly improve the multi-target compound hit rate and avoid patent protection. Combined with National University of Singapore, We have developed the support vector machine (SVM) multi-target screening system, which can meet the requirements of a wide range of drug screening. By using this system, the multiple target compounds were identified and synthesized by our lab.

(4) Tumor metabolomics and proteomics

Because there are a great variety of intracellular metabolites and proteins, and their properties are great different. Using the traditional analysis methods will lead to a large amount of information loss. Aiming to these problems, our research group is dedicated to the development of new strategies for targeted analysis of metabolites and proteomics in biological samples. Using these strategies, a more comprehensive metabolites and proteins information can be obtained. Our main research interest is the use of a variety of derivate means to derivatize the same kind of metabolites of proteins. It could largely increase their detection sensitivity and finally appiled for clinical sample analysis, which could provide a technical platform for the discovery of tumor biomarkers.

(5) Conjugated polymer-based bioanalysis, cell imaging, and drug delivery

Conjugated polymers have received considerable attention and have been widely studied in fluorescent biosensing and cell imaging. We focuse on the following areas: 1) design and synthesis of novel fluorescent probes for sensing and drug delivery; 2) develop biosensing methods targeting different biomarkers for the application of diagnosis and post evaluation; 3) cell imaging study for characterizing apoptosis and autophagy process.

Tumor detection based on RFD probes: We got some probes which could response to metabolites of MDA-MB-231 using SELEX screening. A partial probes could response and bind to metabolites of MDA-MB-231 with high specific advantage. These probes also showed higher effect on recognization to tumor tissue.

Pokemon signal transduction pathways: Our results demonstrated a negative correlation between pokemon expression and survival rate of breast cancer patents. Pokemon could be a negative factor for prognosis.

Origins of multi-target drugs: We compared the species origins of 939 approved and 369 clinical-trial drugs with those of 119 preclinical drugs and 19,721 bioactive natural products, and found that these drugs are clustered into144 of the 6,763 known species families in nature, with 80% of the approved drugs and 67% of the clinical-trial drugs concentrated in 17 and 30 drug-proliﬁc families, respectively. This suggested that the drug distribution of drugs is clustered, and drugs are derived mostly from preexisting drug productive families, which provides clues for future bioprospecting and drug design.

Figure 3. Distribution of drug-productive families. (National Academy of Sciences of the United States of America, 108, 12943-12948)

Identification and optimization of excellent lead compounds ： Usually, a scaffold can derived thousands of compounds. How to identify or optimize lead compounds? By a systematic survey of new molecular entities approved by FDA, we identify favorable and unfavorable properties of lead compounds, which can be applied in future drug development efforts. （ Nature biotechnology 2014, 32 (10), 979-80）

Peptide de Novo sequencing and protein quantification research: A novel stable isotope N-phosphorylation labeling strategy for peptide de novo sequencing and protein quantification based on organic phosphorus chemistry. The labeling reactiion could be performed easily and completed within 40 min in a one-pot reaction without additional cleanup procedures. By using nano liquid chromatography chip/time-of-flight mass spectrometry (nano LC-chip/TOF MS) for the protein quantification, the obtained results showed excellent correlation of the measured ratios to theoretical ratios with relative errors ranging from 0.5% to 6.7% and relative standard deviation of less than 10.6%, indicating that the developed method was reproducible and precise. The method development based on organic phosphorus chemistry offered a new approach for quantitative proteomics by using novel stable isotope labeling reagents.

Conjugated polyelectrolyte-based fluorescence assays for caspases, phosphatases, and proteases: We have developed conjugated polyelectrolyte-based fluorescence assays for caspase 3 and 8, phosphatases, and proteases. Such simple, convenient, and sensitive methods can be generalized to other similar targets for further application in disease diagnosis and evaluation.

Honors and awards

2011 “the ministry of science and technology ‘11th five-year plan’ national outstanding

contribution prize in science and technology plan execution”

2011 “State Council special allowance”

2010 “Special Allowance of Shenzhen Municipal”

2008 “the third Prize of Guangdong Province Science and Technology Awards”

2008 “Shenzhen science and Technology Innovation Award”

2008 “Shenzhen "double hundred" talent plan”

2007 “New Century Excellent Talent of the Ministry of Education”

2006 “Guang Dong Provincial Model Worker”

Selected publications

1. Zhang, W.; Zhang, B.; Zhang, W.; Yang, T.; Wang, N.; Gao, C.; Tan, C.; Liu, H.; Jiang, Y*., Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors. Eur. J. Med. Chem. 2016, 116, 59-70.

2. Wang, Y.; Gao, D.; Chu, B.; Gao, C.; Cao, D.; Liu, H.; Jiang, Y*., Exposure of CCRF-CEM cells to acridone derivative 8a triggers tumor death via multiple mechanisms. Proteomics 2016, 16 (7), 1177-1190.

3. Chen, Y.; Gao, D.; Liu, H.; Lin, S.; Jiang, Y*., Drug cytotoxicity and signaling pathway analysis with three-dimensional tumor spheroids in a microwell-based microfluidic chip for drug screening. Anal. Chim. Acta 2015, 898, 85-92.

4. Mao, Y.; Liu, M.; Tram, K.; Gu, J.; Salena, B. J.; Jiang, Y*..; Li, Y., Optimal DNA Templates for Rolling Circle Amplification Revealed by In Vitro Selection. Chemistry-a European Journal 2015, 21 (22), 8069-8074.

5. Tao, L.; Zhu, F.; Qin, C.; Zhang, C.; Chen, S.; Zhang, P.; Zhang, C.; Tan, C.; Gao, C.; Chen, Z.; Jiang, Y*.; Chen, Y. Z., Clustered Distribution of Natural Product Leads of Drugs in the Chemical Space as Influenced by the Privileged Target-Sites. Scientific Reports 2015, 5.

6. Zhang, B.; Chen, K.; Wang, N.; Gao, C.; Sun, Q.; Li, L.; Chen, Y.; Tan, C.; Liu, H.; Jiang, Y*., Molecular design, synthesis and biological research of novel pyridyl acridones as potent DNA-binding and apoptosis-inducing agents. Eur. J. Med. Chem. 2015, 93, 214-226.

7. Mao, Y.; Chen, Y.; Li, S.; Lin, S.; Jiang, Y*.., A Graphene-Based Biosensing Platform Based on Regulated Release of an Aptameric DNA Biosensor. Sensors (Basel, Switzerland) 2015, 15 (11), 28244-56.

8. Gao, C.; Li, B.; Zhang, B.; Sun, Q.; Li, L.; Li, X.; Chen, C.; Tan, C.; Liu, H.; Jiang, Y*., Synthesis and biological evaluation of benzimidazole acridine derivatives as potential DNA-binding and apoptosis-inducing agents. Bioorg. Med. Chem. 2015, 23 (8), 1800-1807.

9. Li, X.; Gao, C.; Yang, T.; Zhang, B.; Tan, C.; Liu, H.; Jiang, Y*., A POCl3-mediated synthesis of substituted fused azoacridones derivatives. Rsc Advances 2015, 5 (36), 28670-28678.

10. He, S.; Qu, L.; Shen, Z.; Tan, Y.; Zeng, M.; Liu, F.; Jiang, Y*.; Li, Y., Highly Specific Recognition of Breast Tumors by an RNA-Cleaving Fluorogenic DNAzyme Probe. Analytical Chemistry 2015, 87 (1), 569-577.

11. Chu, B.; Liu, F.; Li, L.; Ding, C.; Chen, K.; Sun, Q.; Shen, Z.; Tan, Y.; Tan, C.; Jiang, Y*., A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. Cell death & disease 2015, 6, e1686.

12. Chen, K.; Chu, B.-z.; Liu, F.; Li, B.; Gao, C.-m.; Li, L.-l.; Sun, Q.-s.; Shen, Z.-f.; Jiang, Y*., New benzimidazole acridine derivative induces human colon cancer cell apoptosis in vitro via the ROS-JNK signaling pathway. Acta Pharmacologica Sinica 2015, 36 (9), 1074-1084.

13. Gao, F.; Liu, F.; Zheng, J.; Zeng, M.; Jiang, Y*., A Catalytic DNA Probe with Stem-loop Motif for Human T47D Breast Cancer Cells. Analytical Sciences 2015, 31(8), 815-822.

14. Liu, H.; Li, X.; Liu, F.; Tan, Y.; Jiang, Y*., A simple and novel amide ligand based on quinoline derivative used for palladium-catalyzed Suzuki coupling reaction. Journal Of Organometallic Chemistry 2015, 794, 27-32.

15. Tao, L.; Zhu, F.; Xu, F.; Chen, Z.; Jiang, Y*.; Chen, Y. Z., Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. Pharmacological Research 2015, 102, 123-131.

16. Qin, C.; Tao, L.; Phang, Y. H.; Zhang, C.; Chen, S. Y.; Zhang, P.; Tan, Y.; Jiang, Y*.; Chen, Y. Z., The Assessment of the Readiness of Molecular Biomarker-Based Mobile Health Technologies for Healthcare Applications. Scientific Reports 2015, 5.

17. Tao, L.; Zhu, F.; Qin, C.; Zhang, C.; Xu, F.; Tan, C. Y.; Jiang, Y*.; Chen, Y. Z., Nature's contribution to today's pharmacopeia. Nature biotechnology 2014, 32 (10), 979-80.

18. Zhang, B.; Li, X.; Li, B.; Gao, C.; Jiang, Y*., Acridine and its derivatives: a patent review (2009-2013). Expert Opinion on Therapeutic Patents 2014, 24 (6), 647-664.

19. Xin, T.; Zhang, C.; Tan, C.; Jiang, Y*., Biological Evaluation and Structure Modification of (S)-3-Aminopyrrolidine Derivatives. Chemical Research in Chinese Universities 2014, 30 (1), 91-97.

20. Wu, Q.; Gao, D.; Wei, J.; Jin, F.; Xie, W.; Jiang, Y*.; Liu, H., Development of a novel multi-layer microfluidic device towards characterization of drug metabolism and cytotoxicity for drug screening. Chemical Communications 2014, 50 (21), 2762-2764.

21. Li, B.; Gao, C.-M.; Sun, Q.-S.; Li, L.-L.; Tan, C.-Y.; Liu, H.-X.; Jiang, Y*., Novel synthetic acridine-based derivatives as topoisomerase I inhibitors. Chin. Chem. Lett. 2014, 25 (7), 1021-1024.

22. Gao, D.; Jin, F.; Liu, H.; Wang, Y.; Jiang, Y*., Metabonomic study on the antitumor effect of flavonoid derivative 3d in HepG2 cells and its action mechanism. Talanta 2014, 118, 382-388.

23. Chen, X.; Gao, D.; Liu, F.; Gao, X.; Wang, S.; Zhao, Y.; Liu, H.; Jiang, Y*., A novel quantification method for analysis of twenty natural amino acids in human serum based on N-phosphorylation labeling using reversed-phase liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta 2014, 836, 61-71.

24. Ding, C.; Zhang, C. L.; Zhang, M. L.; Chen, Y. Z.; Tan, C. Y.; Tan, Y.; Jiang, Y*., Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. Future Med Chem 2014, 6 (16), 1771-1789.

25. Qu, L.; Ali, M. M.; Aguirre, S. D.; Liu, H.; Jiang, Y*.; Li, Y., Examination of Bacterial Inhibition Using a Catalytic DNA. PLoS One 2014, 9 (12).

26. Chen, Z.; Liu, F.; Zhang, N.; Cao, D.; Liu, M.; Tan, Y.; Jiang, Y*., p38 beta, A Novel Regulatory Target of Pokemon in Hepatic Cells. Int. J. Mol. Sci. 2013, 14 (7), 13511-13524.

27. Jin, F.; Gao, D.; Wu, Q.; Liu, F.; Chen, Y.; Tan, C.; Jiang, Y*., Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor. Bioorg. Med. Chem. 2013, 21 (18), 5694-5706.

28. Jin, F.; Gao, D.; Zhang, C.; Liu, F.; Chu, B.; Chen, Y.; Chen, Y. Z.; Tan, C.; Jiang, Y*., Exploration of 1-(3-chloro-4-(4-oxo-4H-chromen-2-yl)phenyl)-3-phenylurea derivatives as selective dual inhibitors of Raf1 and JNK1 kinases for anti-tumor treatment. Bioorg. Med. Chem. 2013, 21 (3), 824-831.

29. Jin, X. L.; Sun, Q. S.; Liu, F.; Yang, H. W.; Liu, M.; Liu, H. X.; Xu, W.; Jiang, Y*., microRNA 21‐mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation. Journal of Cellular Biochemistry 2013, 114, 1625-1633.

30. Lang, X.; Li, L.; Chen, Y.; Sun, Q.; Wu, Q.; Liu, F.; Tan, C.; Liu, H.; Gao, C.; Jiang, Y*., Novel synthetic acridine derivatives as potent DNA-binding and apoptosis-inducing antitumor agents. Bioorg. Med. Chem. 2013, 21 (14), 4170-4177.

31. Lang, X.-L.; Sun, Q.-S.; Chen, Y.-Z.; Li, L.-L.; Tan, C.-Y.; Liu, H.-X.; Gao, C.-M.; Jiang, Y*., Novel synthetic 9-benzyloxyacridine analogue as both tyrosine kinase and topoisomerase I inhibitor. Chin. Chem. Lett. 2013, 24 (8), 677-680.

32. Liu, R.; Tan, Y.; Zhang, C.; Wu, J.; Mei, L.; Jiang, Y*.; Tan, C., A real-time fluorescence turn-on assay for trypsin based on a conjugated polyelectrolyte. Journal of Materials Chemistry B 2013, 1 (10), 1402-1405.

33. Wu, J.; Tan, Y.; Xie, Y.; Wu, Y.; Zhao, R.; Jiang, Y*.; Tan, C., Diazobenzene-containing conjugated polymers as dark quenchers. Chemical Communications 2013, 49 (97), 11379-11381.

34. Zhang, N.-N.; Sun, Q.-S.; Chen, Z.; Liu, F.; Jiang, Y*., Homeostatic regulatory role of Pokemon in NF-kappa B signaling: stimulating both p65 and I kappa B alpha expression in human hepatocellular carcinoma cells. Molecular and Cellular Biochemistry 2013, 372 (1-2), 57-64.

35. Gao, D.; Liu, H.; Lin, J.-M.; Wang, Y.; Jiang, Y*., Characterization of drug permeability in Caco-2 monolayers by mass spectrometry on a membrane-based microfluidic device. Lab on a Chip 2013, 13 (5), 978-985.

36. Wang, Y.; Gao, D.; Chen, Z.; Li, S.; Gao, C.; Cao, D.; Liu, F.; Liu, H.; Jiang, Y*., Acridone Derivative 8a Induces Oxidative Stress-Mediated Apoptosis in CCRF-CEM Leukemia Cells: Application of Metabolomics in Mechanistic Studies of Antitumor Agents. Plos One 2013, 8 (5), e63572.

37. Gao, C. M.; Li, S. F.; Lang, X. L.; Liu, H. X.; Liu, F.; Tan, C. Y.; Jiang, Y*., Synthesis and evaluation of 10-(3,5-dimethoxy)benzyl-9(10H)-acridone derivatives as selective telomeric G-quadruplex DNA ligands. Tetrahedron 2012, 68 (38), 7920-7925.

38. Gao, X.; Wu, H.; Lee, K.-C.; Liu, H.; Zhao, Y.; Cai, Z.; Jiang, Y*., Stable Isotope N-Phosphorylation Labeling for Peptide de Novo Sequencing and Protein Quantification Based on Organic Phosphorus Chemistry. Analytical chemistry 2012, 84 (23), 10236-10244.

39. Han, B. C.; Ma, X. H.; Zhao, R. Y.; Zhang, J. X.; Wei, X. N.; Liu, X. H.; Liu, X.; Zhang, C. L.; Tan, C. Y.; Jiang, Y*.; Chen, Y. Z., Development and experimental test of support vector machines virtual screening method for searching Src inhibitors from large compound libraries. Chem Cent J 2012, 6.

40. Jin, F.; Zhang, N.; Tan, C.; Gao, D.; Zhang, C.; Liu, F.; Chen, Z.; Gao, C.; Liu, H.; Li, S.; Jiang, Y*., 2'-Chloro-4'-aminoflavone Derivatives Selectively Targeting Hepatocarcinoma Cells: Convenient Synthetic Process, G2/M Cell Cycle Arrest and Apoptosis Triggers. Archiv Der Pharmazie 2012, 345 (7), 525-534.

41. Jin, Y. B.; Luan, X. D.; Liu, H. X.; Gao, C. M.; Li, S. F.; Cao, D. L.; Li, X. Y.; Cai, Z. W.; Jiang, Y*., Pharmacokinetics and metabolite identification of a novel VEGFR-2 and Src dual inhibitor 6-chloro-2-methoxy-N-(2-methoxybenzyl) acridin-9-amine in rats by liquid chromatography tandem mass spectrometry. Talanta 2012, 89, 70-76.

42. Zhu, F.; Ma, X. H.; Qin, C.; Tao, L.; Liu, X.; Shi, Z.; Zhang, C. L.; Tan, C. Y.; Chen, Y. Z.; Jiang, Y*., Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs. Plos One 2012, 7 (7).

43. Zhao, R.; Xie, Y. H.; Tan, Y.; Tan, C. Y.; Jiang, Y*., Binding of a bcl-2 Family Inhibitor to Bovine Serum Albumin: Fluorescence Quenching and Molecular Docking Study. Protein and Peptide Letters 2012, 19 (9), 949-954.

44. Zhang, X.; Tan, Y.; Zhao, R.; Chu, B.; Tan, C.; Jiang, Y*., Site-directed Mutagenesis Study of the Ile140 in Conserved Hydrophobic Core of Bcl-x(L). Protein and Peptide Letters 2012, 19 (9), 991-996.

45. Zhang, J. X.; Han, B. C.; Wei, X. N.; Tan, C. Y.; Chen, Y. Z.; Jiang, Y*., A Two-Step Target Binding and Selectivity Support Vector Machines Approach for Virtual Screening of Dopamine Receptor Subtype-Selective Ligands. Plos One 2012, 7 (6).

46. Zhang, J.; Jia, J.; Zhu, F.; Ma, X.; Han, B.; Wei, X.; Tan, C.; Jiang, Y*.; Chen, Y., Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Molecular bioSystems 2012, 8 (10), 2645-56.

47. Zhang, C. L.; Tan, C. Y.; Ding, H. W.; Xin, T.; Jiang, Y*., Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials. Current Pharmaceutical Design 2012, 18 (20), 2921-2935.

48. Yang, X. F.; Zu, X. Y.; Tang, J.; Xiong, W.; Zhang, Y.; Liu, F.; Jiang, Y*., Zbtb7 suppresses the expression of CDK2 and E2F4 in liver cancer cells: Implications for the role of Zbtb7 in cell cycle regulation. Molecular Medicine Reports 2012, 5 (6), 1475-1480.

49. Xie, Y. H.; Zhao, R.; Tan, Y.; Zhang, X.; Liu, F.; Jiang, Y*.; Tan, C. Y., Conjugated Polymer-Based Real-Time Fluorescence Caspase Assays. ACS Applied Materials & Interfaces 2012, 4 (1), 405-410.

50. Xie, Y. H.; Tan, Y.; Liu, R. X.; Zhao, R.; Tan, C. Y.; Jiang, Y*., Continuous and Sensitive Acid Phosphatase Assay Based on a Conjugated Polyelectrolyte. ACS Applied Materials & Interfaces 2012, 4 (8), 3784-3787.

51. Tian, J.; Jiang, Y*., Insulin upregulates the expression of zinc finger and BTB domain-containing 7A in HepG2 cells. Molecular Medicine Reports 2012, 6 (6), 1379-1384.

52. Tan, Y.; Zhang, X.; Xie, Y. H.; Zhao, R.; Tan, C. Y.; Jiang, Y*., Label-free fluorescent assays based on aptamer-target recognition. Analyst 2012, 137 (10), 2309-2312.

53. Liu, K.; Liu, F.; Zhang, N. N.; Liu, S. Y.; Jiang, Y*., Pokemon Silencing Leads to Bim-Mediated Anoikis of Human Hepatoma Cell QGY7703. Int. J. Mol. Sci. 2012, 13(5), 5818-5831.

54. Lin, J. S.; Liu, F.; Jiang, Y*., Antisense Technologies Targeting Fatty Acid Synthetic Enzymes. Recent Patents on Anti-Cancer Drug Discovery 2012, 7 (2), 198-206.

55. Lin, J.; Jin, X.; Bu, Y.; Cao, D.; Zhang, N.; Li, S.; Sun, Q.; Tan, C.; Gao, C.; Jiang, Y*., Efficient synthesis of RITA and its analogues: derivation of analogues with improved antiproliferative activity via modulation of p53/miR-34a pathway. Organic & Biomolecular Chemistry 2012, 10 (48), 9734-9746.

56. Lang, X. L.; Luan, X. D.; Gao, C. M.; Jiang, Y*., Recent Progress of Acridine Derivatives with Antitumor Activity. Progress in Chemistry 2012, 24 (8), 1497-1505.

57. Zu, X.; Ma, J.; Liu, H.; Liu, F.; Tan, C.; Yu, L.; Wang, J.; Xie, Z.; Cao, D.; Jiang, Y*., Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression. Breast Cancer Res. 2011, 13, R26.

58. Zhu, F.; Qin, C.; Tao, L.; Liu, X.; Shi, Z.; Ma, X.; Jia, J.; Tan, Y.; Cui, C.; Lin, J.; Tan, C.; Jiang, Y*.; Chen, Y., Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (31), 12943-12948, S12943/1-S12943/139.

59. Zhao, R.; Tan, C.; Xie, Y.; Gao, C.; Liu, H.; Jiang, Y*., One step synthesis of azo compounds from nitroaromatics and anilines. Tetrahedron Lett. 2011, 52 (29), 3805-3809.

60. Zhang, Y.; Zu, X. Y.; Luo, W. S.; Tang, S. S.; Jiang, Y*., siRNA Induced CyclinB1 Knockdown Sensitizes HepG2 Cells to Daunorubicin. Prog. Biochem. Biophys. 2011, 38 (6), 551-557.

61. Zhang, D.; Liu, H.; Zhang, S.; Chen, X.; Li, S.; Zhang, C.; Hu, X.; Bi, K.; Chen, X.; Jiang, Y*., An effective method for de novo peptide sequencing based on phosphorylation strategy and mass spectrometry. Talanta 2011, 84 (3), 614-622.

62. Zhang, C.; Zhai, X.; Wan, F.; Gong, P.; Jiang, Y*., 2-Chloro-1- 4-(2-fluorobenzyl)piperazin-1-yl ethanone. Acta Crystallographica Section E-Structure Reports Online 2011, 67, O708-U2523.

63. Zhang, C.; Tan, C.; Zu, X.; Zhai, X.; Liu, F.; Chu, B.; Ma, X.; Chen, Y.; Gong, P.; Jiang, Y*., Exploration of (S)-3-aminopyrrolidine as a potentially interesting scaffold for discovery of novel Abl and PI3K dual inhibitors. Eur. J. Med. Chem. 2011, 46 (4), 1404-1414.

64. Luan, X.; Gao, C.; Zhang, N.; Chen, Y.; Sun, Q.; Tan, C.; Liu, H.; Jin, Y.; Jiang, Y*., Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors. Bioorg. Med. Chem. 2011, 19 (11), 3312-3319.

65. Luan, X.; Gao, C.; Sun, Q.; Tan, C.; Liu, H.; Jin, Y.; Jiang, Y*., Novel synthetic azaacridine analogues as topoisomerase 1 inhibitors. Chem. Lett. 2011, 40 (7), 728-729.

66. Li, Y.; Tan, C.; Gao, C.; Zhang, C.; Luan, X.; Chen, X.; Liu, H.; Chen, Y.; Jiang, Y*., Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorg. Med. Chem. 2011, 19 (15), 4529-4535.

67. Li, S.; Liu, H.; Jin, Y.; Lin, S.; Cai, Z.; Jiang, Y*., Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2011, 879 (24), 2369-2375.

68. Hu, X.; Gao, C.; Tan, C.; Zhang, C.; Zhang, H.; Li, S.; Liu, H.; Jiang, Y*., Design and Synthesis of N-phosphoryl Peptide Modified Podophyllotoxin Derivatives as Potent Anticancer Agents. Protein and Peptide Letters 2011, 18 (12), 1258-1264.

69. Chen, X. W.; Liu, H. X.; Jin, Y. B.; Li, S. F.; Bi, X.; Chung, S.; Zhang, S. S.; Jiang, Y*., Separation, identification and quantification of tetrodotoxin and its analogs by LC-MS without calibration of individual analogs. Toxicon 2011, 57 (6), 938-943.

Yuyang JIANG, Ph.D.

About TM

Health Care

Education

Research

News & Events